Cargando…
Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways
Epidermal growth factor receptor (EGFR)-targeted therapies have been effective in some cancers, but not in hepatocellular carcinoma (HCC). The aim of this study was to investigate the drug potential to overcome multi-drug resistance in HCC cells. Thirteen drug-sensitive HCC cells were assessed using...
Autores principales: | Kim, Heesue, Lim, Ho Yeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230015/ https://www.ncbi.nlm.nih.gov/pubmed/22147992 http://dx.doi.org/10.3346/jkms.2011.26.12.1563 |
Ejemplares similares
-
Irreversible EGFR Inhibitor EKB-569 Targets Low-LET γ-Radiation-Triggered Rel Orchestration and Potentiates Cell Death in Squamous Cell Carcinoma
por: Aravindan, Natarajan, et al.
Publicado: (2011) -
Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants
por: Xie, Xianhe, et al.
Publicado: (2020) -
Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors
por: Sun, Juan, et al.
Publicado: (2015) -
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
por: Kim, Jung Eun, et al.
Publicado: (2017) -
Downregulation of HNRNPM inhibits cell proliferation and migration of hepatocellular carcinoma through MAPK/AKT signaling pathway
por: Qiao, Lu, et al.
Publicado: (2022)